HLA-A and neoplasm: Hence, during tumor progression and development of resistance in rrDLBCLs, we observed higher gene mutation frequencies in PIM1, CD58, FAS, HLA-A, and TNFRSF14 as compared to dDLBCL consistent with other studies analyzing global genomic sequencing data [19, 27, 43] and illustrated the loss of immune surveillance (CD58, HLA-A) as well as immune suppression (FAS, TNFRSF14, PIM1) [19, 43].